1、Novartis inSocietyIntegrated Report 2024 02Novartis in Society Integrated Report 2024ContentsAbout this report 03Chairs letter 04CEOs letter 05About NovartisOur company 07Our medicines 08Our global operations 09Our people,culture and values 10Strategy and business modelOperating environment 12Strate

2、gy 13Business model 15Material topics 16Business reviewFinancial performance 19Innovation performance 20Operational performance 21Key assets in our R&D pipeline 22Sustainability mattersEnvironmental matters 25Climate 25Nature 30Social matters 34People and culture 34Human rights 37Patient health and

3、safety 38Access to medicines:a shared responsibility 40Governance and integrity matters 42Ethical business conduct 42Animal welfare 45Political engagement 45Supply chain management 46Corporate governance,risk management and compensationCorporate governance 48Our Board of Directors 51Our Executive Co

4、mmittee 52Risk management 53Compensation 56AppendixPerformance indicators 60Disclosures in accordance with Art.964b Swiss Code of Obligations 63Task Force on Climate-related Financial Disclosures(TCFD)index 642024 climate scenario analysis in accordance with the recommendations of the Task Force on

5、Climate-related Financial Disclosures(TCFD)65Global Reporting Initiative(GRI)content index 69Independent practitioners limited assurance report on selected Sustainability Information of Novartis AG 72Abbreviations 74Cover:Kate Kostelyk and her labrador Dakoda in Mims,Florida.Kate has IgA nephropathy

6、(IgAN),an autoimmune kidney disease.She works with the IgAN Foundation to raise awareness of the disease and push for better treatments.03Novartis in Society Integrated Report 2024About this reportThe Novartis in Society Integrated Report is our main disclosure for nonfinancial information.It has be